for people ages 18-85 (full criteria)
at San Francisco, California and other locations
study started
estimated completion
Principal Investigator
by John P Cello, MD
Photo of John P Cello
John P Cello



Determine if IV ketorolac is an effective agent in the prevention of post-ERCP pancreatitis. Determine if IV ketorolac provides improved post-procedure analgesia. Determine if systemic mediators of inflammation are reduced in patients receiving IV ketorolac following ERCP.


Acute pancreatitis is the most common major complication of both diagnostic and therapeutic endoscopic retrograde cholangiopancreatography (ERCP), accounting for substantial morbidity and an annual expenditure of approximately 150 million annually.(1,2) Non-steroidal anti-inflammatory agents (NSAIDs) have been shown to be effective in multiple prospective randomized controlled trial for the prevention of post-ERCP pancreatitis.(3-6) NSAIDs are postulated to inhibit phospholipase A2 and prostaglandin synthesis, which plays an important role in the inflammatory cascade in acute pancreatitis. Rectal suppository indomethacin (a potent COX-2 inhibitor) has been effective in preventing post-ERCP pancreatitis in clinical trials and is now recommended for routine use for ERCP by the European Society of Gastrointestinal Endoscopy.(7) Toradol® (ketorolac), an NSAID available in IV form, is a more potent COX-2 inhibitor and analgesic than indomethacin.(8,9) Ketorolac is routinely used postoperatively following major surgery to assist in pain control particularly following orthopedic procedures. IV ketorolac has never been evaluated for the prevention of post-ERCP pancreatitis.


Pancreatitis Ketorolac Toradol


You can join if…

Open to people ages 18-85

  • All patients presenting to SFGH for ERCP
  • Age 18-85
  • Do not meet

You CAN'T join if...

Exclusion Criteria:

  • Acute pancreatitis at the time of ERCP
  • Use of NSAIDs in the previous week
  • Peptic ulcer disease
  • Severe renal dysfunction
  • Pregnancy
  • Lithium therapy
  • allergy to ketorolac


  • San Francisco General Hospital
    San Francisco California 94117 United States
  • UCSF/San Francisco General Hospital
    San Francisco California 94132/94110 United States

Lead Scientist at UCSF

  • John P Cello, MD
    Professor, Medicine. Authored (or co-authored) 126 research publications.


not yet accepting patients
Start Date
Completion Date
University of California, San Francisco
Phase 4
Study Type
Last Updated